DBV Technologies

DBV climbs as peanut allergy safety data come in clean
Fierce Biotech
Mon, 11/20/17 - 09:53 am
peanut allergy
DBV Technologies
Viaskin Peanut
A new peanut allergy vaccine failed in a trial, but the company wants it approved anyway
Stat
Sun, 10/22/17 - 09:48 am
vaccines
food allergies
peanut allergy
DBV Technologies
Viaskin Peanut
The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
Stat
Tue, 10/3/17 - 11:50 am
biotech
Axovant Sciences
intepirdine
SAGE Therapeutics
brexanolone
AbbVie
risankizumab
Global Blood Therapeutics
GBT-440
DBV Technologies
Viaskin Peanut
Cytokinetics
Amicus Therapeutics
ATB200
Spark Therapeutics
Bluebird Bio
Revance Therapeutics
RT002
The sector’s most valuable unpartnered assets – up for grabs or on the shelf?
EP Vantage
Tue, 08/22/17 - 09:55 am
R&D
Kite Pharma
Incyte
Portola Pharmaceuticals
DBV Technologies
Axovant
AveXis
Europe Biotechs Aim to Catch Americans as Investors Embrace IPOs
Bloomberg
Sat, 07/25/15 - 09:58 am
biotech
IPOs
Europe
DBV Technologies
GW Pharma
DBV files to raise $245M to fuel race for peanut allergy market
Fierce Biotech
Thu, 07/16/15 - 06:32 pm
DBV Technologies
peanut allergy
Viaskin
Viaskin Peanut
DBV makes a beeline for Phase III as peanut allergy race hots up
Fierce Biotech
Thu, 06/25/15 - 09:29 am
DBV Technologies
vaccines
food allergies
peanut allergy
Viaskin Peanut
Peanut Allergy Patch Quest Has French Company Spurning Suitors
Bloomberg
Tue, 12/2/14 - 09:57 am
peanut allergy
DBV Technologies
Viaskin

Pages